6-acetylamino-pyridine-2-carboxylic acid amide | 13537-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-acetylamino-pyridine-2-carboxylic acid amide
• 英文别名: 6-Acetylamino-pyridin-2-carbonsaeure-amid；6-Acetamidopyridine-2-carboxamide
• CAS: 13537-98-9
• 化学式: C₈H₉N₃O₂
• mdl: MFCD20542581
• 分子量: 179.178
• InChiKey: CFRLTVJDXXTGFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  85.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-acetylamino-pyridine-2-carboxylic acid amide 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以95%的产率得到2-acetamido-6-cyanopyridine
  参考文献：
  名称：

  Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury

  摘要：

  A series of 2-guanidino-4-pyridylthiazole derivatives were synthesized and evaluated for anti-aspirin-ulcer, gastric antisecretory, and histamine-H-2-receptor-antagonist activities. Several compounds showed superior anti-aspirin-ulcer activity to that of clinically used H-2-antagonists in the rat. Among them, 4-[6-(acetamidomethyl)pyridin-2-yl]-2-guanidinothiazole (8) demonstrated potent inhibitory activities against gastric lesions caused by two kinds of nonsteroidal antiinflammatory drugs, aspirin and indomethacin, respectively, in addition to strong antisecretory activity. Compound 8 possessed a preventable ability for the aspirin-induced reduction of the gastric mucosal blood flow at an intragastric administration of 32 mg/kg in the rat. On the other hand, famotidine (32 mg/kg) exhibited no significant effect and ranitidine (100 mg/kg) aggravated the blood flow in this system.

  DOI：

  10.1021/jm00027a007
• 作为产物：
  描述：

  6-乙酰氨基吡啶羧酸 在 盐酸 、 甲醇 、 ammonium hydroxide 、 溶剂黄146 作用下， 生成 6-acetylamino-pyridine-2-carboxylic acid amide
  参考文献：
  名称：

  Ferrari; Marcon, Farmaco, Edizione Scientifica, 1959, vol. 14, p. 594,596

  摘要：

  DOI：

文献信息

• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20010034445A1

  公开（公告）日：2001-10-25

  Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

  式(I)的化合物被披露，它们是在治疗骨质疏松症中有用的维特龙蛋白受体拮抗剂。
• Katsura Yousuke, Inoue Yoshikazu, Tomishi Tetsuo, Ishikawa Hirohumi, Taka+, J. Med. Chem, 37 (1994) N 1, S 57-66
  作者：Katsura Yousuke, Inoue Yoshikazu, Tomishi Tetsuo, Ishikawa Hirohumi, Taka+

  DOI：——

  日期：——
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0895475A1

  公开（公告）日：1999-02-10
• EP0895475A4
  申请人：——

  公开号：EP0895475A4

  公开（公告）日：2000-08-23
• [EN] VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE VITRONECTINE
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1997024122A1

  公开（公告）日：1997-07-10

  (EN) Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis.(FR) Composés de la formule (I) constituant des antagonistes du récepteur de la vitronectine utiles pour le traitement de l'ostéoporose.